The Secretary of State for Health and Social Care & Ors v Lundbeck Limited & Ors

This Court of Appeal decision was about whether NHS bodies could continue a very large competition damages claim in the Competition Appeal Tribunal after earlier High Court proceedings had been transferred there. The underlying competition infringement had already been established by a final European Commission decision concerning agreements linked to citalopram.

The defendants argued that the transferred case was really just the old High Court stand-alone claim in a new venue, so it stayed time-barred under the Limitation Act 1980. The Court of Appeal rejected that argument. It held that the CAT follow-on claim, filed under the Tribunal rules within the CAT time limit, was not defeated by the earlier High Court limitation problem.

The commercial background was a market-entry dispute in the pharmaceutical sector. Lundbeck’s basic patent for citalopram had expired, but it still held some process patents. Generic manufacturers were preparing to launch cheaper versions. According to the Commission findings summarised by the Court of Appeal, Lundbeck entered agreements with generic competitors that involved transfers of value linked to those competitors staying out of the market.

The NHS bodies later claimed that these arrangements kept citalopram prices higher than they should have been and caused major loss to public healthcare purchasers. They sought damages said to exceed £500 million. Their first move was a stand-alone High Court claim in 2019, before the European appeals process had finished. After the infringement decision became final in March 2021, the claimants shifted to the CAT route and filed a CAT claim form before the CAT’s two-year limitation period expired.

The central issue was not whether the original agreements breached competition law. That had already been established for follow-on purposes once the Commission decision became final. The real question was procedural but commercially important: after the High Court proceedings were transferred to the CAT, were the CAT proceedings governed by the CAT’s follow-on limitation rules or by the Limitation Act 1980 rules that applied to the earlier stand-alone High Court claim?

The defendants also ran a second argument based on contractual estoppel. They said the wording of the transfer order preserved their accrued limitation rights, so the claimants had effectively agreed not to rely on the CAT limitation regime to keep the claim alive.

The Court of Appeal dismissed the appeal. On Ground 1, it agreed with the CAT that the claim filed in the Tribunal under Rule 30, within the applicable CAT time limit, could proceed. The court treated the CAT rules as comprehensive and self-contained. It also emphasised that transfer rules are meant to improve efficiency, not to extinguish otherwise valid claims.

On Ground 2, the court rejected the contractual estoppel argument. It held that the transfer order preserved accrued rights in relation to the High Court claim as constituted there, not rights that would automatically defeat a new and otherwise valid CAT follow-on claim. The court considered it commercially unrealistic to read the order as requiring the claimants to take every step needed to start valid CAT proceedings while simultaneously agreeing to destroy that claim.

The wider lesson is about competitor conduct. The court’s summary of the Commission decision draws a clear line: settling a patent dispute is generally legitimate, but a settlement becomes dangerous where it prevents a potential competitor from entering the market and includes a transfer of value linked to staying out. That is the practical competition warning for businesses.

This matters beyond pharmaceuticals. Similar risk can arise where one business pays, compensates, supplies, or otherwise rewards a rival for delaying launch, limiting sales, or avoiding a territory or customer group. If the commercial effect is to reduce competition rather than resolve a genuine dispute on ordinary terms, the arrangement may attract serious scrutiny and later damages claims.

If your business is negotiating with a competitor, especially around intellectual property, supply, distribution or launch timing, build a competition check into the deal process. This case shows how a commercial arrangement can later be reframed as a restriction on competition with major damages consequences.

If you are already in litigation, also check forum and limitation strategy carefully. A move between the High Court and the CAT can change how claims are framed and what procedural steps are needed. The wording of consent orders should be reviewed closely, but this case shows courts will read them in context rather than assume the parties intended commercially pointless outcomes.